Navigation Links
Analysis of the Global Type 2 Diabetes Therapeutics Market
Date:11/21/2013

London (PRWEB) November 21, 2013

Market Opportunities for Differentiated Therapeutics

Type 2 diabetes is one of the most significant global health concerns of modern times. The size of the diabetes therapeutics market has stimulated a vast and growing pipeline of potential new therapies aimed at the unmet needs of tighter glucose control, improved safety profiles, and greater convenience to patients. This research service evaluates the global market for the pharmaceutical management of type 2 diabetes from 2009 to 2017, with 2012 as the base year. Segmentation by drug type (insulin and non-insulin therapeutics) and regional breakdown are provided. Included are products available in the market, products in development, and patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed.

Methodology

•The information contained in this research service was derived from a variety of relevant primary and secondary sources.
•Primary interviews were conducted with industry participants in positions such as chairman and CEO, director of investor relations, director of business development, chief business officer, media relations, and international key opinion leaders (KOL).
•Secondary data sources include disease and public health organization Web sites [International Diabetes federation (IDF), World Health Organization (WHO), American Diabetes Association (ADA)]; company publications (annual reports, the US Securities and Exchange Commission (SEC) filings, investor presentations, earnings transcripts, and press releases; government public sources; pharmaceutical industry databases; and published articles in scientific and medical journals.
•For the US, revenue forecasting is performed using a robust, data-driven, bottom-up, patient-based approach. Marketed drugs and potential new entrants in Phase 3 of development and beyond are individually forecast, and aggregate figures are provided. For other regions, forecasting is performed using a top-down model.

Key Findings

•Type 2 diabetes is one of the most significant global health concerns of modern times. According to the International Diabetes Federation, more than X million people have been diagnosed with diabetes, and an additional Xmillion are living with undiagnosed diabetes.
•No longer a disease exclusive to developed countries, type 2 diabetes is rapidly overwhelming developing countries such as China and India as more countries adopt the westernized lifestyle that largely contributes to the increasing prevalence.
•The global revenue earned from sales of drugs to treat type 2 diabetes was approximately $X billion in 2012. The rapidly increasing incidence of the disease globally will drive this figure to approximately $X billion by 2017.
•The market for type 2 diabetes therapeutics in China is growing rapidly and is expected to outpace Europe to become the second largest market by 2017. South Korea and Vietnam are also forecast to experience rapid growth.
•Overall, the growth rate of the insulin segment exceeds that of the non-insulin segment.
•The market for diabetes drugs has many barriers to entry, particularly for the insulin segment, which requires a great deal of specialization. The inherent risk involved includes failure to receive marketing approval after a relatively large investment of time and money, which limits this market to those organizations with the necessary expertise and capital.
•Due to the chronic nature of the disease and the numerous co-morbidities that make this patient population particularly sensitive to long-term drug safety, the clinical and regulatory hurdles are considerable. However, the immense size of the potential market has stimulated a vast and growing pipeline of potential new therapies aimed at addressing the unmet needs of tighter glucose control, improved safety profiles, and greater convenience to patients.
•The insulin segment of this market, estimated to be approximately X% of the total type 2 diabetes therapeutics market in 2012, is boosted by the improvements seen with modern insulins including improved pharmacokinetic profiles and reduced risk of hypoglycemia—the main drawback to insulin therapy. Several insulin analogues in development have the potential to offer better overall outcomes resulting from their liver-targeted action.
•The non-insulin segment has been enhanced by the arrival of a novel drug class with the first-in-class sodium-glucose transporter-2 (SGLT2) Forxiga (dapagliflozin) launched in Europe in late 2012 and close competitor Invokana (canagliflozin) approved in the US in March 2013. This class, the first novel class since 2006, offers important added benefits over existing therapies such as weight loss and blood pressure lowering.

Scope and Segmentation

Geographic coverage: Global
Study period: 2009–2017
Base year: 2012
Forecast period: 2013–2017
Monetary unit: US Dollars

•This research service evaluates the global market for type 2 diabetes therapeutics. It does not evaluate other diabetes care markets such as glucose meters and supplies, insulin syringes, insulin pumps, or glucose tablets and other nutritionals.
•Included are insulin and insulin analogues, oral antidiabetic drugs (OAD) and injectable antidiabetic drugs apart form insulin.
•In-depth analysis is provided for the major markets of the US and Europe. The emerging markets of China, South Korea, Malaysia, Indonesia, Vietnam, and India are also evaluated with an emphasis on the regional environment.
•Units are defined as patients. Treated patient numbers, when estimated, are derived from annual sales revenue and annual cost of therapy.
•The price is the annual cost of therapy. Average annual cost of therapy is based on the average wholesale price (AWP) per drug, as reported in Thomson Reuters Red Book. Hospital or clinic-associated expenses are not included in the cost of therapy.
•Indication-specific annual revenue, as reported, is used when available; otherwise, estimates are used.

Key Questions This Study Will Answer

•Is the market growing, how long will it continue to grow, and at what rate? Which segments and geographic regions are experiencing the fastest growth?
•How will the competitive landscape be affected by new product launches and patent expiries? How do the product profiles of new products compare to existing products?
•What are the remaining unmet needs of diabetes patients? How can participants and emerging competitors meet these needs?
•What are the major trends affecting the growth of this market? What are the biggest risks for participants or potential participants?
•What are the biggest opportunities and risks in emerging markets? What is the relative impact of social, economic, pricing constraints, and regulatory factors on emerging market penetration?
•How competitive is this market? Is this market trending toward increasing or decreasing competitiveness?

Table of Contents

1. Executive Summary
•Key Findings
•Scope and Segmentation
•Key Questions This Study Will Answer
•Market Engineering Measurements
•CEO’s Perspective
•Key Companies to Watch
•Executive Summary—3 Big Predictions
2. Market Overview
•Market Background
•Market Segmentation
•Market Segmentation Discussion
•Global Market Perspective
•Defining Healthcare Trends in the Future
3. Competitive Playbook
•New Market Opportunities
•Merger, Acquisition, and Partnership Assessment
4. Driver, Restraints, and Trends—Total Type 2 Diabetes Therapeutics Market
•Market Drivers
•Market Restraints
5. Forecasts and Trends—Total Type 2 Diabetes Therapeutics Market
•Market Engineering Measurements
•Forecast Assumptions and Definitions
•Revenue Forecast
•Revenue Forecast Discussion
•Percent Revenue Forecast by Region
•Revenue Forecast by Region
6. Competitive Environment
•Competitive Landscape—Insulin Segment, Count of Marketed and Pipeline Products
•Marketed Product Synopsis—Insulin Segment
•Marketed Product Profiles—Insulin Segment Rapid-acting Insulin
•Marketed Product Profiles—Insulin Segment Intermediate-acting/Premix Insulin
•Marketed Product Profiles—Insulin Segment Basal Insulin
•Pipeline Analysis—Insulin Segment Products in Late-stage Clinical Development
•Pipeline Analysis—Insulin Segment Products in Mid-stage Clinical Development
•Pipeline Analysis—Insulin Segment Products in Early-stage Clinical Development
•Competitive Landscape—Non-insulin Segment Count of Marketed and Pipeline Products
•Competitive Landscape—Non-insulin Segment Late-stage and Marketed Products
•Competitive Landscape—Non-insulin Segment Early-stage Pipeline Products
•Marketed Product Synopsis—Non-insulin Segment First Line Standard of Care Products
•Marketed Product Synopsis—Non-insulin Segment Add-on Products
•Marketed Product Profiles—Non-insulin Segment DPP-4 Class
•Marketed Product Profiles—Non-insulin Segment GLP-1 Class
•Marketed Product Profiles—Non-insulin Segment SGLT2 Class
•Pipeline Analysis—Non-insulin Segment Products in Late-stage Clinical Development
•Pipeline Analysis—Non-insulin Segment Products in Mid-stage Clinical Development
•Pipeline Analysis—Non-insulin Segment Products in Early-stage Clinical Development
•Market Share Evolution
•Market Share Analysis
•Top Competitors
•Timeline of Product Launches
•Patent Expirations—Insulin Segment
•Patent Expirations—Non-insulin Segment
•Exclusivity Periods of Key Products—Modern Insulins
•Exclusivity Periods of Key Products—Non-insulin Segment
•Cardiovascular Outcomes Trials Timeline
•Comparative Product Profiles of Promising Late-stage Candidates
•Comparative Efficacy Analysis
•Comparative Efficacy Analysis Discussion
7. Insulin Segment Breakdown
•Insulin Segment Key Findings
•Market Engineering Measurements
•Revenue Forecast
•Revenue Forecast Discussion
8. Non-insulin Segment Breakdown
•Non-insulin Segment Key Findings
•Market Engineering Measurements
•Revenue Forecast
•Revenue Forecast Discussion
9. United States (US) Breakdown
•Insulin Segment Revenue Forecast
•Insulin Segment Revenue Forecast by Class
•Insulin Segment Revenue Forecast Discussion
•Insulin Segment Type 2 Diabetes Prevalence and Treated Patient Forecast
•Insulin Segment Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion
•Non-insulin Segment Revenue Forecast
•Non-insulin Segment Revenue Forecast by Class
•Non-insulin Segment Revenue Forecast Discussion
•Non-insulin Segment Type 2 Diabetes Prevalence and Treated Patient Forecast
•Non-insulin Segment Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion
•Pricing Analysis
•Market Analysis
•PESTLE Analysis
10. United Kingdom (UK) Breakdown
•The UK Diabetes Outlook
•Insulin Segment Revenue Forecast
•Insulin Segment Revenue Forecast Discussion
•Non-insulin Segment Revenue Forecast
•Non-insulin Segment Revenue Forecast Discussion
•Regulatory Policy Framework
•Pricing and Reimbursement
•Type 2 Diabetes Prevalence Forecast
•Type 2 Diabetes Prevalence Forecast Discussion
•Market Analysis
11. Germany Breakdown
•Germany Diabetes Outlook
•Insulin Segment Revenue Forecast
•Insulin Segment Revenue Forecast Discussion
•Non-insulin Segment Revenue Forecast
•Non-insulin Segment Revenue Forecast Discussion
•Regulatory Policy Framework
•Pricing and Reimbursement
•Type 2 Diabetes Prevalence Forecast
•Type 2 Diabetes Prevalence Forecast Discussion
•Market Analysis
12. France Breakdown
•France Diabetes Outlook
•Insulin Segment Revenue Forecast
•Insulin Segment Revenue Forecast Discussion
•Non-insulin Segment Revenue Forecast
•Non-insulin Segment Revenue Forecast Discussion
•Regulatory Policy Framework
•Pricing and Reimbursement
•Type 2 Diabetes Prevalence Forecast
•Type 2 Diabetes Prevalence Forecast Discussion
•Market Analysis
13. Italy Breakdown
•Italy Diabetes Outlook
•Insulin Segment Revenue Forecast
•Insulin Segment Revenue Forecast Discussion
•Non-insulin Segment Revenue Forecast
•Non-insulin Segment Revenue Forecast Discussion
•Regulatory Policy Framework
•Pricing and Reimbursement
•Type 2 Diabetes Prevalence Forecast
•Type 2 Diabetes Prevalence Forecast Discussion
•Market Analysis
14. Spain Breakdown
•Spain Diabetes Outlook
•Insulin Segment Revenue Forecast
•Insulin Segment Revenue Forecast Discussion
•Non-insulin Segment Revenue Forecast
•Non-insulin Segment Revenue Forecast Discussion
•Regulatory Policy Framework
•Pricing and Reimbursement
•Type 2 Diabetes Prevalence Forecast
•Type 2 Diabetes Prevalence Forecast Discussion
•Market Analysis
15. Benelux Breakdown
•Benelux Diabetes Outlook
•Insulin Segment Revenue Forecast
•Insulin Segment Revenue Forecast Discussion
•Non-insulin Segment Revenue Forecast
•Non-insulin Segment Revenue Forecast Discussion
•Regulatory Policy Framework
•Pricing and Reimbursement
•Type 2 Diabetes Prevalence Forecast
•Type 2 Diabetes Prevalence Forecast Discussion
•Market Analysis
16. Scandinavia Breakdown
•Scandinavia Diabetes Outlook
•Insulin Segment Revenue Forecast
•Insulin Segment Revenue Forecast Discussion
•Non-insulin Segment Revenue Forecast
•Non-insulin Segment Revenue Forecast Discussion
•Regulatory Policy Framework
•Pricing and Reimbursement
•Type 2 Diabetes Prevalence Forecast
•Type 2 Diabetes Prevalence Forecast Discussion
•Market Analysis
17. China Breakdown
•Market Overview
•Insulin Segment Revenue Forecast
•Insulin Segment Revenue Forecast Discussion
•Non-insulin Segment Revenue Forecast
•Non-insulin Segment Revenue Forecast Discussion
•Pricing Analysis
•Type 2 Diabetes Prevalence and Treated Patient Forecast
•Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion
•Market Analysis
18. South Korea Breakdown
•South Korea Diabetes Outlook
•Insulin Segment Revenue Forecast
•Insulin Segment Revenue Forecast Discussion
•Non-insulin Segment Revenue Forecast
•Non-insulin Segment Revenue Forecast Discussion
•Pricing Analysis
•Type 2 Diabetes Prevalence and Treated Patient Forecast
•Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion
•Market Analysis
19. Malaysia Breakdown
•Malaysia Diabetes Outlook
•Insulin Segment Revenue Forecast
•Insulin Segment Revenue Forecast Discussion
•Non-insulin Segment Revenue Forecast
•Non-insulin Segment Revenue Forecast Discussion
•Pricing Analysis
•Type 2 Diabetes Prevalence and Treated Patient Forecast
•Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion
•Market Analysis
20. Indonesia Breakdown
•Indonesia Diabetes Outlook
•Insulin Segment Revenue Forecast
•Insulin Segment Revenue Forecast Discussion
•Non-insulin Segment Revenue Forecast
•Non-insulin Segment Revenue Forecast Discussion
•Pricing Analysis
•Type 2 Diabetes Prevalence and Treated Patient Forecast
•Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion
•Market Analysis
21. Vietnam Breakdown
•Vietnam Diabetes Outlook
•Insulin Segment Revenue Forecast
•Insulin Segment Revenue Forecast Discussion
•Non-insulin Segment Revenue Forecast
•Non-insulin Segment Revenue Forecast Discussion
•Pricing Analysis
•Type 2 Diabetes Prevalence and Treated Patient Forecast
•Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion
•Market Analysis
22. India Breakdown
•Insulin Segment Revenue Forecast
•Insulin Segment Revenue Forecast Discussion
•Non-insulin Segment Revenue Forecast
•Non-insulin Segment Revenue Forecast Discussion
•Pricing Analysis
•Type 2 Diabetes Prevalence and Treated Patient Forecast
•Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion
•Market Analysis
23. Customer and End-user Analysis
•KOL Commentary
24. Key Companies to Watch
•Companies to Watch
•DiaMedica, Inc.
•Eli Lilly
•Elcelyx Therapeutics, Inc.
•Novo Nordisk
25. The Last Word
•The Last Word—3 Big Predictions
•The Last Word—Discussion
•Legal Disclaimer
26. Appendix
•Drivers Explained
•Restraints Explained
•Decision Support Database
•Additional Sources of Information on Diabetes
•Market Engineering Methodology
•Learn More—Next Steps

List of Exhibits

•Analysis of the Global Type 2 Diabetes Therapeutics Market
•Market Opportunities for Differentiated Therapeutics
•Type 2 diabetes is one of the most significant global health concerns of modern times. The size of the diabetes therapeutics market has stimulated a vast and growing pipeline of potential new therapies aimed at the unmet needs of tighter glucose control, improved safety profiles, and greater convenience to patients. This research service evaluates the global market for the pharmaceutical management of type 2 diabetes from 2009 to 2017, with 2012 as the base year. Segmentation by drug type (insulin and non-insulin therapeutics) and regional breakdown are provided. Included are products available in the market, products in development, and patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed.
•Total Type 2 Diabetes Therapeutics Market: Market Engineering Measurements, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Diagnostic Criteria, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Market Segmentation, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Growth Rate Breakdown by Geographic Region,
•Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Market Outlook, Global, 2012 and 2022
•Total Type 2 Diabetes Therapeutics Market: Game-changing Strategies, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Market Outlook, Global, 2007–2013
•Total Type 2 Diabetes Therapeutics Market: Key Market Drivers, Global, 2013–2017
•Total Type 2 Diabetes Therapeutics Market: Key Market Restraints, Global, 2013–2017
•Total Type 2 Diabetes Therapeutics Market: Market Engineering Measurements, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Revenue Forecast, Global, 2009–2017
•Total Type 2 Diabetes Therapeutics Market: Major New Product Launches, Global, 2013–2017
•Total Type 2 Diabetes Therapeutics Market: Percent Revenue Forecast by Region, Global, 2009–2017
•Total Type 2 Diabetes Therapeutics Market: Revenue Forecast by Region, Global, 2009–2017
•Total Type 2 Diabetes Therapeutics Market: Competitive Landscape—Insulin Segment, Count of Marketed and Pipeline Products by Type and Phase, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Competitive Landscape—Insulin Segment, Marketed and Pipeline Products by Type, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Insulin Segment, Marketed Product Synopsis, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Insulin Segment Marketed Product Profiles, Rapid-acting Insulin, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Insulin Segment Marketed Product Profiles, Intermediate-acting/Premix Insulin, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Insulin Segment Marketed Product Profiles, Basal Insulin, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Insulin Segment, Late-stage Product Synopsis, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Insulin Segment, Mid-stage Product Synopsis, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Insulin Segment—Early-stage Product Synopsis, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Competitive Landscape—Non-insulin Segment, Count of Marketed and Pipeline Products by Type and Phase, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Competitive Landscape—Non-Insulin Segment, Late-stage and Marketed Products by Drug Class, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Competitive Landscape—Non-Insulin Segment, Early-stage Pipeline Products by Drug Class, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment, Standard of Care Marketed Product Synopsis, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment, Add-on Marketed Product Synopsis, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment Marketed Product Profiles, DPP-4s, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment Marketed Product Profiles, GLP-1s, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment Marketed Product Profiles, SGLT2s, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Non-Insulin Segment, Late-stage Product Synopsis, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Non-Insulin Segment, Mid-stage Product Synopsis, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Non-Insulin Segment, Early-stage Product Synopsis, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Absolute Market Share Trend by Revenue, Global, 2009 and 2012
•Total Type 2 Diabetes Therapeutics Market: Company Market Share Analysis of Top 5 Participants, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: SWOT Analysis, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Timeline of Product Launches, Global, 2010–2018
•Total Type 2 Diabetes Therapeutics Market: Patent Expirations, Insulin Segment, Global, 2000–2030
•Total Type 2 Diabetes Therapeutics Market: Patent Expirations—Non-insulin Segment, Global, 2000–2030
•Total Type 2 Diabetes Therapeutics Market: Exclusivity Periods of Major Products—Modern Insulins, Global, 2000–2030
•Total Type 2 Diabetes Therapeutics Market: Exclusivity Periods of Major Products—Non-insulin Segment, Global, 2000–2030
•Total Type 2 Diabetes Therapeutics Market: Cardiovascular Outcomes Trials Timeline, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Comparative Product Profiles of Promising Late-stage Candidates, Global, 2012
•Total Type 2 Diabetes Therapeutics Market: Comparative HbA1c Lowering of Selected Marketed Drugs, Global, 2012
•Total Type 2 Diabetes Market: Comparative HbA1c Lowering of Selected Marketed Drugs, Global, 2012
•Insulin Segment: Percent Sales Breakdown, Global, 2012
•Insulin Segment: Market Engineering Measurements, Global, 2012
•Insulin Segment: Revenue Forecast, Global, 2009–2017
•Non-insulin Segment: Percent Sales Breakdown, Global, 2012
•Non-insulin Segment: Market Engineering Measurements, Global, 2012
•Non-insulin Segment: Revenue Forecast, Global, 2009–2017
•Insulin Segment: Revenue Forecast, US, 2009–2017
•Insulin Segment: Revenue Forecast by Class, US, 2009–2017
•Insulin Segment: Type 2 Diabetes Prevalence and Treated Patient Forecast, US, 2009–2017
•Non-insulin Segment: Revenue Forecast, US, 2009–2017
•Non-insulin Segment: Revenue Forecast by Class, US, 2009–2017
•Non-insulin Segment: Evolution of Market Share by Drug Class, US, 2012 and 2017
•Non-insulin Segment: Type 2 Diabetes Prevalence and Treated Patient Forecast, US, 2009–2017
•Type 2 Diabetes Therapeutics Market: Pricing Analysis, US, 2012
•Type 2 Diabetes Therapeutics Market: PESTLE Analysis, US, 2012
•Type 2 Diabetes Therapeutics Market: Diabetes Outlook, UK, 2012 and 2030
•Insulin Segment: Revenue Forecast, UK, 2009–2017
•Non-insulin Segment: Revenue Forecast, UK, 2009–2017
•Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, UK, 2012
•Type 2 Diabetes Therapeutics Market: Prevalence Forecast, UK, 2009–2017
•Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Germany, 2012 and 2030
•Insulin Segment: Revenue Forecast, Germany, 2009–2017
•Non-insulin Segment: Revenue Forecast, Germany, 2009–2017
•Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Germany, 2012
•Type 2 Diabetes Therapeutics Market: Reimbursement Status, Germany, 2012
•Type 2 Diabetes Therapeutics Market: Prevalence Forecast, Germany, 2009–2017
•Type 2 Diabetes Therapeutics Market: Diabetes Outlook, France, 2012 and 2030
•Insulin Segment: Revenue Forecast, France, 2009–2017
•Non-insulin Segment: Revenue Forecast, France, 2009–2017
•Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, France, 2012
•Type 2 Diabetes Therapeutics Market: Prevalence Forecast, France, 2009–2017
•Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Italy, 2012 and 2030
•Insulin Segment: Revenue Forecast, Italy, 2009–2017
•Non-insulin Segment: Revenue Forecast, Italy, 2009–2017
•Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Italy, 2012
•Type 2 Diabetes Therapeutics Market: Prevalence Forecast, Italy, 2009–2017
•Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Spain, 2012 and 2030
•Insulin Segment: Revenue Forecast, Spain, 2009–2017
•Non-insulin Segment: Revenue Forecast, Spain, 2009–2017
•Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Spain, 2012
•Type 2 Diabetes Therapeutics Market: Prevalence Forecast, Spain, 2009–2017
•Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Benelux, 2012 and 2030
•Insulin Segment: Revenue Forecast, Benelux, 2009–2017
•Non-insulin Segment: Revenue Forecast, Benelux, 2009–2017
•Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Belgium, 2012
•Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, the Netherlands, 2012
•Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Luxembourg, 2012
•Type 2 Diabetes Therapeutics Market: Prevalence Forecast, Benelux, 2009–2017
•Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Scandinavia, 2012 and 2030
•Insulin Segment: Revenue Forecast, Scandinavia, 2009–2017
•Non-insulin Segment: Revenue Forecast, Scandinavia, 2009–2017
•Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Norway, 2012
•Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Sweden, 2012
•Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Denmark, 2012
•Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Finland, 2012
•Type 2 Diabetes Therapeutics Market: Prevalence Forecast, Scandinavia, 2009–2017
•Insulin Segment: Revenue Forecast, China, 2009–2017
•Non-insulin Segment: Revenue Forecast, China, 2009–2017
•Type 2 Diabetes Therapeutics Market: Pricing Analysis, China, 2012
•Type 2 Diabetes Therapeutics Market: Prevalence and Treated Patient Forecast, China, 2009–2017
•Type 2 Diabetes Therapeutics Market: Range of Reported Disease Prevalence Estimates, China, 2012
•Type 2 Diabetes Therapeutics Market: Diabetes Outlook, South Korea, 2012 and 2030
•Insulin Segment: Revenue Forecast, South Korea, 2009–2017
•Non-insulin Segment: Revenue Forecast, South Korea, 2009–2017
•Type 2 Diabetes Therapeutics Market: Pricing Analysis, South Korea, 2012
•Type 2 Diabetes Therapeutics Market: Prevalence and Treated Patient Forecast, South Korea, 2009–2017
•Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Malaysia, 2012 and 2030
•Insulin Segment: Revenue Forecast, Malaysia, 2009–2017
•Non-insulin Segment: Revenue Forecast, Malaysia, 2009–2017
•Type 2 Diabetes Therapeutics Market: Pricing Analysis, Malaysia, 2012
•Type 2 Diabetes Therapeutics Market: Prevalence and Treated Patient Forecast, Malaysia, 2009–2017
•Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Indonesia, 2012 and 2030
•Insulin Segment: Revenue Forecast, Indonesia, 2009–2017
•Non-insulin Segment: Revenue Forecast, Indonesia, 2009–2017
•Type 2 Diabetes Therapeutics Market: Prevalence and Treated Patient Forecast, Indonesia, 2009–2017
•Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Vietnam, 2012 and 2030
•Insulin Segment: Revenue Forecast, Vietnam, 2009–2017
•Non-insulin Segment: Revenue Forecast, Vietnam, 2009–2017
•Type 2 Diabetes Therapeutics Market: Pricing Analysis, Vietnam, 2012
•Type 2 Diabetes Market: Prevalence and Treated Patient Forecast, Vietnam, 2009–2017
•Insulin Segment: Revenue Forecast, India, 2009–2017
•Non-insulin Segment: Revenue Forecast, India, 2009–2017
•Type 2 Diabetes Therapeutics Market: Pricing Analysis, India, 2012
•Type 2 Diabetes Therapeutics Market: Prevalence and Treated Patient Forecast, India, 2009–2017
•Decision Support Database: Prevalence of Type-2 Diabetes, Global, 2008–2018
•Decision Support Database: Percent of Prevalence of Type-2 Diabetes, Global, 2008–2018

Read the full report:

Analysis of the Global Type 2 Diabetes Therapeutics Market

http://www.reportbuyer.com/pharma_healthcare/treatments/analysis_global_type_diabetes_therapeutics_market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com

Read the full story at http://www.prweb.com/releases/2013/11/prweb11359012.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved


Related medicine news :

1. Lung Cancer Screening Might Pay Off, Analysis Shows
2. SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples
3. Analysis Finds Clinical Trials Often Small, of Poor Quality
4. Zinc Pills May Shorten Colds, Analysis Suggests
5. Biochip-based device for cell analysis
6. Analysis will examine safety of in-hospital underwater births
7. Genome-wide analysis shows previously undetected abnormalities in parents of affected children
8. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
9. Meta-analysis: Interventions improve depression in cancer patients
10. Terrorism and the Olympics by-the-numbers: Analysis from UMD-based START
11. Genome analysis of brain tumors showing the way to new treatment strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
Breaking Medicine Technology: